These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 31915861)

  • 1. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.
    Appiah-Kusi E; Petros N; Wilson R; Colizzi M; Bossong MG; Valmaggia L; Mondelli V; McGuire P; Bhattacharyya S
    Psychopharmacology (Berl); 2020 Apr; 237(4):1121-1130. PubMed ID: 31915861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
    Bergamaschi MM; Queiroz RH; Chagas MH; de Oliveira DC; De Martinis BS; Kapczinski F; Quevedo J; Roesler R; Schröder N; Nardi AE; Martín-Santos R; Hallak JE; Zuardi AW; Crippa JA
    Neuropsychopharmacology; 2011 May; 36(6):1219-26. PubMed ID: 21307846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.
    Bhattacharyya S; Wilson R; Appiah-Kusi E; O'Neill A; Brammer M; Perez J; Murray R; Allen P; Bossong MG; McGuire P
    JAMA Psychiatry; 2018 Nov; 75(11):1107-1117. PubMed ID: 30167644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report.
    Davies C; Appiah-Kusi E; Wilson R; Blest-Hopley G; Bossong MG; Valmaggia L; Brammer M; Perez J; Allen P; Murray RM; McGuire P; Bhattacharyya S
    Eur Arch Psychiatry Clin Neurosci; 2022 Apr; 272(3):461-475. PubMed ID: 34480630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study.
    Spinella TC; Stewart SH; Naugler J; Yakovenko I; Barrett SP
    Psychopharmacology (Berl); 2021 Jul; 238(7):1965-1977. PubMed ID: 33813611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol.
    Davies C; Bossong MG; Martins D; Wilson R; Appiah-Kusi E; Blest-Hopley G; Zelaya F; Allen P; Brammer M; Perez J; McGuire P; Bhattacharyya S
    Psychol Med; 2024 Apr; 54(5):993-1003. PubMed ID: 37845827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.
    Linares IM; Zuardi AW; Pereira LC; Queiroz RH; Mechoulam R; Guimarães FS; Crippa JA
    Braz J Psychiatry; 2019; 41(1):9-14. PubMed ID: 30328956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial.
    Dixon T; Cadenhead KS
    Trials; 2023 Nov; 24(1):775. PubMed ID: 38037108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
    O'Neill A; Wilson R; Blest-Hopley G; Annibale L; Colizzi M; Brammer M; Giampietro V; Bhattacharyya S
    Psychol Med; 2021 Mar; 51(4):596-606. PubMed ID: 31994476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis.
    Davies C; Wilson R; Appiah-Kusi E; Blest-Hopley G; Brammer M; Perez J; Murray RM; Allen P; Bossong MG; McGuire P; Bhattacharyya S
    Transl Psychiatry; 2020 Sep; 10(1):311. PubMed ID: 32921794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
    Hahn B
    Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease.
    de Faria SM; de Morais Fabrício D; Tumas V; Castro PC; Ponti MA; Hallak JE; Zuardi AW; Crippa JAS; Chagas MHN
    J Psychopharmacol; 2020 Feb; 34(2):189-196. PubMed ID: 31909680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
    García-Gutiérrez MS; Navarrete F; Gasparyan A; Austrich-Olivares A; Sala F; Manzanares J
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33228239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial.
    Gundugurti PR; Banda N; Yadlapalli SSR; Narala A; Thatikonda R; Kocherlakota C; Kothapalli KS
    Asian J Psychiatr; 2024 Jul; 97():104073. PubMed ID: 38797087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder.
    Bolsoni LM; Crippa JAS; Hallak JEC; Guimarães FS; Zuardi AW
    Psychopharmacology (Berl); 2022 May; 239(5):1499-1507. PubMed ID: 35029706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk.
    Davies C; Bossong MG; Martins D; Wilson R; Appiah-Kusi E; Blest-Hopley G; Allen P; Zelaya F; Lythgoe DJ; Brammer M; Perez J; McGuire P; Bhattacharyya S
    Schizophr Bull Open; 2023 Jan; 4(1):sgad022. PubMed ID: 39145348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stressor-Cortisol Concordance Among Individuals at Clinical High-Risk for Psychosis: Novel Findings from the NAPLS Cohort.
    Cullen AE; Addington J; Bearden CE; Stone WS; Seidman LJ; Cadenhead KS; Cannon TD; Cornblatt BA; Mathalon DH; McGlashan TH; Perkins DO; Tsuang MT; Woods SW; Walker EF
    Psychoneuroendocrinology; 2020 May; 115():104649. PubMed ID: 32197198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats.
    Resstel LB; Tavares RF; Lisboa SF; Joca SR; Corrêa FM; Guimarães FS
    Br J Pharmacol; 2009 Jan; 156(1):181-8. PubMed ID: 19133999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
    Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.